XT
SPRY icon

XTX Topco’s ARS Pharmaceuticals SPRY Stock Holding History

XTX Topco’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$586K Sell
73,187
-202,921
-73% -$1.75M 0.01% 2308
2026
Q1 		$2.22M Buy
276,108
+238,907
+642% +$2.29M 0.04% 749
2025
Q4 		$433K Sell
37,201
-106,435
-74% -$1.04M 0.01% 1733
2025
Q3 		$1.44M Buy
143,636
+126,543
+740% +$1.82M 0.07% 354
2025
Q2 		$298K Sell
17,093
-32,554
-66% -$470K 0.01% 1438
2025
Q1 		$625K Buy
49,647
+17,429
+54% +$210K 0.03% 859
2024
Q4 		$340K Buy
32,218
+14,975
+87% +$210K 0.03% 1110
2024
Q3 		$250K Buy
+17,243
New +$205K 0.02% 1310
2023
Q4 		– Sell
-10,117
Closed -$38.2K – 2105
2023
Q3 		$38.2K Buy
+10,117
New +$66.4K 0.01% 1305
2022
Q3 		– Sell
-10,001
Closed -$42K – 1362
2022
Q2 		$42K Sell
10,001
-12,136
-55% -$42.3K 0.02% 760
2022
Q1 		$78K Buy
22,137
+3,321
+18% +$14.5K 0.03% 546
2021
Q4 		$125K Buy
+18,816
New +$153K 0.07% 434

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

XTX Topco's SPRY Position: Q2 2026 in Review

XTX Topco reduced its ARS Pharmaceuticals (SPRY) stake by 73% in Q2 2026, selling an estimated $1.75M and leaving 73,187 shares worth $586K. The position accounts for 0.01% of the portfolio, ranked #2308.

XTX Topco first reported a position in SPRY in Q4 2021 and has held it in 12 quarters since. The position peaked at $2.22M in Q1 2026. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • XTX Topco held 73,187 shares of ARS Pharmaceuticals worth $586K as of Q2 2026.
  • XTX Topco sold 202,921 ARS Pharmaceuticals shares in Q2 2026, an estimated $1.75M.
  • ARS Pharmaceuticals made up 0.01% of XTX Topco's portfolio in Q2 2026, its #2308 holding.
  • XTX Topco first reported a position in ARS Pharmaceuticals in Q4 2021 and has held it in 12 quarters since.
  • XTX Topco's ARS Pharmaceuticals position peaked at $2.22M in Q1 2026.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.